Using mathematical modelling to help explain the differential increase in HIV incidence in New South Wales, Victoria and Queensland: Importance of other sexually transmissible infections

Sexual Health

Volumn 5, Issue 2, 2008, Pages 169-187

  Hoare, Alexander ^a   Wilson, David P ^a   Regan, David G ^a   Kaldor, John ^a   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Australia; Men who have sex with men

Indexed keywords

ARTICLE; AUSTRALIA; CONDOM; DIAGNOSTIC TEST; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MALE HOMOSEXUAL; MATHEMATICAL MODEL; PREVALENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VIRUS DIAGNOSIS;

HEALTH PROMOTION; HIV INFECTIONS; HIV SEROPREVALENCE; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; MODELS, STATISTICAL; NEW SOUTH WALES; QUEENSLAND; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES; UNSAFE SEX; VICTORIA;

EID: 44649106549     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH07099     Document Type: Article

References (73)

1. NSW, VIC and QLD Gay Periodic Surveys. 1998-2006.
2. Richters J. HIV/AIDS, Hepatitis C & Related Diseases in Australia: Annual Report of Behaviour 2006, National Centre in HIV Social Research, University of New South Wales: Sydney.
3. Crawford JM, et al. Number of risk acts by relationship status and partner serostatus: Findings from the HIM cohort of homosexually active men in Sydney, Australia. AIDS Behav 2006; 10: 325-31. doi: 10.1007/s10461-005- 9057-3
4. Grierson J, Thorpe R, Pitts M. HIV Futures 5: Life as we know it, monograph series number 60. 2006, The Australian Research Centre in Sex, Health and Society, Latrobe University, Melbourne, Australia.
5. Quinn TC, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-9. doi: 10.1056/NEJM200003303421303
6. National Centre in HIV Social Research Annual Report of Trends in Behaviour. 2006, University of New South Wales: Sydney.
7. Van de Ven P, et al. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 2005; 19: 179-84.
8. Marks G, et al. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39: 446-53. doi: 10.1097/01.qai.0000151079.33935.79
9. Cleary PD, et al. Behavior changes after notification of HIV infection. Am J Public Health 1991; 81: 1586-90.
10. Colfax GN, et al. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002; 16: 1529-35. doi: 10.1097/00002030-200207260-00010
11. McCusker J, et al. Effects of HIV antibody test knowledge on subsequent sexual behaviors in a cohort of homosexually active men. Am J Public Health 1988; 78: 462-7.
12. Saah AJ, et al. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. AIDS 1998; 12: 2107-13. doi: 10.1097/00002030-199816000-00005
13. Smith DK, et al. Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol 1997; 146: 459-69.
14. Valleroy LA, et al. HIV prevalence and associated risks in young men who have sex with men. Young Men's Survey Study Group. JAMA 2000; 284: 198-204. doi: 10.1001/jama.284.2.198
15. Fogarty A , et al. The Health in Men and Positive Health cohorts: A comparison of trends in the health and sexual behaviour of HIV-negative and HIV-positive gay men, 2002-2005, National Centre in HIV Social Research Annual Report of Trends in Behaviour. 2006, University of New South Wales: Sydney.
16. Mao L, et al. "Serosorting" in casual anal sex of HIV-negative gay men is noteworthy and is increasing in Sydney, Australia. AIDS 2006; 20: 1204-6. doi: 10.1097/01.aids.0000226964.17966.75
17. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31: 272-9. doi: 10.2307/2991537
18. Weller SC, Davis KR. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; CD003255.
19. Pinkerton SD, Abtramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44: 1303-12. doi: 10.1016/S0277-9536(96) 00258-4
20. Weller SC. A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Soc Sci Med 1993; 36: 1635-44. doi: 10.1016/0277- 9536(93)90352-5
21. Fitch TJ, et al. Condom Effectiveness: Factors that influence risk reduction. Sex Transm Dis 2002; 29: 811-7. doi: 10.1097/00007435- 200212000-00013
22. Rangsin R, et al. The natural history of HIV-1 infection in young Thai men after seroconversion. J Acquir Immune Defic Syndr 2004; 36: 622-9. doi: 10.1097/00126334-200405010-00011
23. Richardson BA, et al. Comparison of Human Immunodeficiency Virus Type 1 Viral Loads in Kenyan Women, Men, and Infants during Primary and Early Infection. J Virol 2003; 77: 7120-3. doi: 10.1128/JVI.77.12.7120-7123. 2003
24. Simon V, Ho DD, Abdool Karim Q, HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368: 489-504. doi: 10.1016/S0140-6736(06)69157-5
25. Sarr AD, et al. Viral dynamics of primary HIV-1 infection in Senegal, West Africa. J Infect Dis 2005; 191: 1460-7. doi: 10.1086/429409
26. Rodriguez RJ, et al. Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 49-53.
27. Lavreys L, et al. Viral load during primary HIV-1 infection in a cohort of female commercial sex workers in Mombasa, Kenya. Int Conf AIDS, 2000. 13: p. MoPeB2247.
28. Sabin CA, et al. Course of viral load throughout HIV-1 infection. J Acquir Immune Defic Syndr 2000; 23: 172-7.
29. Swindells S, et al. Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr 2002; 30: 154-8.
30. Anekthananon T, et al. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004; 87: 760-7.
31. Bonjoch A, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006; 22: 321-9. doi: 10.1089/aid.2006.22.321
32. Yozviak JL, Doerfler RE, Woodward WC. Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice. HIV Clin Trials 2001; 2: 474-6. doi: 10.1310/T0RR-TGY0-8QWB-8YT2
33. Blower S, et al. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19: 1-14. doi: 10.1097/00002030-200501030-00001
34. Zhang H, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339: 1803-9. doi: 10.1056/NEJM199812173392502
35. Vittinghoff E, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150: 306-11.
36. DeGruttola V, et al. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 1989; 42: 849-56. doi: 10.1016/0895-4356(89) 90098-X
37. Varghese B, et al. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis 2002; 29: 38-43. doi: 10.1097/00007435-200201000-00007
38. Chesson HW, et al. HIV infections and associated costs attributable to syphilis coinfection among African Americans. Am J Public Health 2003; 93: 943-8.
39. Royce RA, et al. Sexual transmission of HIV. N Engl J Med 1997; 336: 1072-8. doi: 10.1056/NEJM199704103361507
40. Johnson AM, et al. Transmission of HIV to heterosexual partners of infected men and women. AIDS 1989; 3: 367-72. doi: 10.1097/00002030- 198906000-00005
41. McCormick AW, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 2007; 44: 1115-22. doi: 10.1086/512816
42. Grulich AE, et al. Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia. Sex Health 2005; 2: 13-8. doi: 10.1071/SH04029
43. Jin F, et al. Epidemic syphilis among homosexually active men in Sydney. Med J Aust 2005; 183: 179-83.
44. Bautista CT, et al. Seroprevalence of and risk factors for HIV-1 infection among South American men who have sex with men. Sex Transm Infect 2004; 80: 498-504. doi: 10.1136/sti.2004.013094
45. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75: 3-17.
46. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2: 33-42. doi: 10.1038/nrmicro794
47. Piot P, Laga M. Genital ulcers, other sexually transmitted diseases, and the sexual transmission of HIV. BMJ 1989; 298: 623-4.
48. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001; 28: 579-97. doi: 10.1097/00007435-200110000-00005
49. Simonsen JN, et al. Human immunodeficiency virus infection among men with sexually transmitted diseases. Experience from a center in Africa. N Engl J Med 1988; 319: 274-8.
50. Read TRH, et al. Rick factors for incident HIV infection in men having sex with men: a case-control study. Sex Health 2007; 4: 35-9. doi: 10.1071/SH06043
51. Crawford JM, et al. Number of risk acts by relationship status and partner serostatus: Findings from the HIM cohort of homosexually active men in Sydney, Australia. AIDS Behav 2006; 10: 325-31. doi: 10.1007/s10461-005- 9057-3
52. Kaufmann GR, et al. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis 1998; 178: 1812-5. doi: 10.1086/314480
53. Schacker TW, et al. Biological and Virologic Characteristics of Primary HIV Infection. Ann Intern Med 1998; 128: 613-20.
54. MAP Workshop. Extending public health surveillance of HIV infection: information from a five cohort workshop. (Multi-cohort Analysis Project). Stat Med 1993; 12: 2065-85. doi: 10.1002/sim.4780122203
55. MAP Workshop. Marker paths. (Multi-cohort Analysis Project). Stat Med 1993; 12: 2099-126. doi: 10.1002/sim.4780122205
56. Law MG, et al. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15: 1287-94. doi: 10.1097/00002030-200107060-00011
57. Kilmarx PH, et al. Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand. J Infect Dis 2000; 181: 1598-606. doi: 10.1086/315469
58. Glenday K, et al. HIV antiretroviral treatment differences by state in Australia. In Preparation, 2007.
59. Bonnet F, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3: 195-9. doi: 10.1046/j.1468-1293.2002.00117.x
60. Keiser O, et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004; 18: 1835-43. doi: 10.1097/00002030-200409030-00013
61. Lewden C, et al. Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiproteases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study. J Infect Dis 2002; 186: 710-4. doi: 10.1086/342047
62. Petoumenos K, Law MG. Risk factors and causes of death in the Australian HIV Observational Database. Sex Health 2006; 3: 103-12. doi: 10.1071/SH05045
63. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6: 99-106. doi: 10.1111/j.1468-1293.2005.00271.x
64. Luo K, et al. The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995; 9: 57-64. doi: 10.1097/00002030- 199501000-00008
65. Costello C, et al. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol 2005; 34: 577-84. doi: 10.1093/ije/dyi023
66. Li Y, et al. Improving survival following AIDS in Australia, 1991-1996. National HIV Surveillance Committee. AIDS 2000; 14: 2349-54. doi: 10.1097/00002030-200010200-00016
67. Wilson DP, Kahn J, Blower SM. Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide. Proc Natl Acad Sci USA 2006; 103: 14228-33. doi: 10.1073/pnas.0509689103
68. Barbour JD, et al. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004; 190: 251-6. doi: 10.1086/422036
69. Egger M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315: 1194-9.
70. Egger M, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29. doi: 10.1016/S0140-6736(02)09411-4
71. Hogg RS, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-4. doi: 10.1001/jama.279.6.450
72. Mocroft A, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-30. doi: 10.1016/S0140-6736(98)03201-2
73. Palella FJJr, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60. doi: 10.1056/NEJM199803263381301